How Sharma was paid
$1.1M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Panna SharmaChief Executive Officer and President | $575,000 | $281,750 | $223,534 | $10,350 | $1,090,634 |
| David R. MargraveChief Financial Officer and Secretary | $413,800 | $162,288 | $166,448 | $10,350 | $752,886 |
| Kishor Bhatia, Ph.D.Chief Scientific Officer | $316,000 | $101,120 | $111,650 | $10,350 | $539,120 |
What changed and why
- $1.1M$1,090,634 CEO total compensation in 2024, up from $684,385 in 2023.
- $224K$223,534 CEO option award was granted in 2024, while no option award was reported for 2023.
- $282K$281,750 CEO cash bonus increased from $149,185 in 2023.
- $575K$575,000 CEO salary increased from $525,300 in 2023.
- $4.35$4.35 per share was the exercise price for 2024 option grants to all named executives.
- $190KDr. Bhatia’s 2025 annual base salary was adjusted to $189,600 after his weekly commitment was reduced to 24 hours.
Other Lantern Pharma proxy statements
- 2026 proxy statement
Panna Sharma paid $763,750 (-30% on the year).
Filed Oct 19, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.